HONG KONG, Aug. 26, 2015 /PRNewswire/ -- Golden Meditech Holdings Limited (SEHK stock code: 801, TWSE stock code: 910801) ("Golden Meditech" or the "Company", together with its subsidiaries, the "Group"), a leading integrated healthcare enterprise in China, is pleased to announce the termination of the agreement entered into between KKR China Healthcare Investment Limited ("KKR") and the Company, in respect of the purchase of the senior convertible notes issued by China Cord Blood Corporation to KKR ("CO CN"). On the same date, Mr. Kam acquired the CO CN from KKR and indirectly held it through his wholly owned company, Magnum Opus 2 International Holdings Limited ("Magnum 2"). In addition, Mr. Kam has undertaken to grant the Company a call option to acquire the CO CN for the same consideration at a later time.
Reference is made to the announcement of the Company dated 4 May 2015, the Company had entered into an agreement with KKR to acquire the CO CN in the principal amount of US$65 million. Pursuant to the agreement, the completion of the transaction is scheduled on or before 31 August 2015. In order to facilitate the completion of the transaction, the Company's Chairman Mr. Kam Yuen has acquired the CO CN from KKR through Magnum 2. The purchase price is no less than US$159.9 million plus interest. Meanwhile, Mr. Kam has undertaken to grant Golden Meditech a call option (for nil consideration) to acquire the CO CN. Golden Meditech would thereafter, if it exercises the call option, pay the same consideration that Magnum 2 paid to KKR. The transaction was completed on 26 August 2015, the first tranche of the payment of US$80 million has already been paid, and the remaining payment will be paid on or before 28 October 2015.
In addition, Mr. Kam's another wholly owned company, Magnum Opus International Holdings Limited ("Magnum 1") also holds the senior convertible notes due 2017 issued by China Cord Blood Corporationin the principal amount of US$25 million. Therefore, assuming full conversions of senior convertible notes held by Mangum 1 and Mangum 2 into CO shares by Golden Meditech, together with Golden Meditech's existing shareholding in CO, the total shareholding will reach approximately 51.7% of the enlarged issued share capital of CO.
For more information about the transaction, please refer to the announcement published by the Company on 26 August 2015 under the link below:http://www.hkexnews.hk/listedco/listconews/SEHK/2015/0826/LTN20150826863.pdf
About Golden Meditech Holdings Limited (SEHK stock code: 801, TWSE stock code: 910801)
Golden Meditech Holdings Limited (www.goldenmeditech.com) is a leading integrated-healthcare enterprise inChina. It is a first-mover in China, having established its dominant positions in several markets including the medical devices market, the cord blood storage market and the hospital management market in the healthcare industry, thanks to its strengths in innovation and market expertise and the ability to capture emerging market opportunities. Going forward, Golden Meditech will continue to pursue a leading position in China's healthcare industry both through organic growth and strategic expansion.